{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:21:07Z","timestamp":1755217267949,"version":"3.43.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,5]]},"DOI":"10.7759\/cureus.89396","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T09:11:34Z","timestamp":1754385094000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Effectiveness of Management Strategies for Stage IV Prostate Cancer: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Okelue E","family":"Okobi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobechukwu J","family":"Okobi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Okobi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Kimble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cherish D","family":"Adesola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebere M","family":"Nwachukwu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael O","family":"Oluwalana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kingsley O","family":"Ozojide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley","family":"Ezulike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.21037\/tau-20-1031","article-title":"Narrative review of management strategies and outcomes in node-positive prostate cancer","volume":"10","author":"D'Rummo KA","year":"2021","unstructured":"D'Rummo KA, Chen RC, Shen X. Narrative review of management strategies and outcomes in node-positive prostate cancer. Transl Androl Urol. 2021, 10:3176-87. 10.21037\/tau-20-1031","journal-title":"Transl Androl Urol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-007-0291-4","article-title":"Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy","volume":"22","author":"Yee EF","year":"2007","unstructured":"Yee EF, White RE, Murata GH, Handanos C, Hoffman RM. Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med. 2007, 22:1305-10. 10.1007\/s11606-007-0291-4","journal-title":"J Gen Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14374","article-title":"A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET\/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol","volume":"122","author":"Hofman MS","year":"2018","unstructured":"Hofman MS, Murphy DG, Williams SG, et al.. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET\/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. BJU Int. 2018, 122:783-93. 10.1111\/bju.14374","journal-title":"BJU Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S303215","article-title":"Evolution of androgen deprivation therapy (ADT) and its new emerging modalities in prostate cancer: an update for practicing urologists, clinicians and medical providers","volume":"14","author":"Choi E","year":"2022","unstructured":"Choi E, Buie J, Camacho J, Sharma P, de Riese WT. Evolution of androgen deprivation therapy (ADT) and its new emerging modalities in prostate cancer: an update for practicing urologists, clinicians and medical providers. Res Rep Urol. 2022, 14:87-108. 10.2147\/RRU.S303215","journal-title":"Res Rep Urol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong AJ","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al.. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019, 37:2974-86. 10.1200\/JCO.19.00799","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2503660","article-title":"Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in Canada","volume":"28","author":"Aprikian A","year":"2025","unstructured":"Aprikian A, Saad F, Wywial E, McLean T, Johnston K, Li Y, Chilelli A. Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in Canada. J Med Econ. 2025, 28:766-77. 10.1080\/13696998.2025.2503660","journal-title":"J Med Econ"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00829-9","article-title":"Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials","volume":"27","author":"Shelan M","year":"2024","unstructured":"Shelan M, Achard V, Appiagyei F, et al.. Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials. Prostate Cancer Prostatic Dis. 2024, 27:422-31. 10.1038\/s41391-024-00829-9","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/13685538.2022.2053954","article-title":"Androgen deprivation therapy and depression in the prostate cancer patients: review of risk and pharmacological management","volume":"25","author":"Alwhaibi A","year":"2022","unstructured":"Alwhaibi A, Alsanea S, Almadi B, Al-Sabhan J, Alosaimi FD. Androgen deprivation therapy and depression in the prostate cancer patients: review of risk and pharmacological management. Aging Male. 2022, 25:101-24. 10.1080\/13685538.2022.2053954","journal-title":"Aging Male"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2017.09.017","article-title":"Effects of androgen deprivation therapy on pain perception, quality of life, and depression in men with prostate cancer","volume":"55","author":"Gagliano-Juc\u00e1 T","year":"2018","unstructured":"Gagliano-Juc\u00e1 T, Travison TG, Nguyen PL, et al.. Effects of androgen deprivation therapy on pain perception, quality of life, and depression in men with prostate cancer. J Pain Symptom Manage. 2018, 55:307-317.e1. 10.1016\/j.jpainsymman.2017.09.017","journal-title":"J Pain Symptom Manage"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA","volume":"35","author":"Oudard S","year":"2017","unstructured":"Oudard S, Fizazi K, Sengel\u00f8v L, et al.. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J Clin Oncol. 2017, 35:3189-97. 10.1200\/JCO.2016.72.1068","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/10732748241274190","article-title":"How we treat metastatic castration-sensitive prostate cancer","volume":"31","author":"Ionescu F","year":"2024","unstructured":"Ionescu F, Zhang J. How we treat metastatic castration-sensitive prostate cancer. Cancer Control. 2024, 31:10732748241274190. 10.1177\/10732748241274190","journal-title":"Cancer Control"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101194","article-title":"Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy","volume":"8","author":"Oing C","year":"2023","unstructured":"Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy. ESMO Open. 2023, 8:101194. 10.1016\/j.esmoop.2023.101194","journal-title":"ESMO Open"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.11.013","article-title":"Clinically localized prostate cancer in 2017: a review of comparative effectiveness","volume":"35","author":"Lavery HJ","year":"2017","unstructured":"Lavery HJ, Cooperberg MR. Clinically localized prostate cancer in 2017: a review of comparative effectiveness. Urol Oncol. 2017, 35:40-1. 10.1016\/j.urolonc.2016.11.013","journal-title":"Urol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.03.021","article-title":"The comparative oncologic effectiveness of available management strategies for clinically localized prostate cancer","volume":"35","author":"Tyson MD","year":"2017","unstructured":"Tyson MD, Penson DF, Resnick MJ. The comparative oncologic effectiveness of available management strategies for clinically localized prostate cancer. Urol Oncol. 2017, 35:51-8. 10.1016\/j.urolonc.2016.03.021","journal-title":"Urol Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi K","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, et al.. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019, 20:686-700. 10.1016\/S1470-2045(19)30082-8","journal-title":"Lancet Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos CE","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, et al.. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018, 36:1080-7. 10.1200\/JCO.2017.75.3657","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker CC","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, et al.. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018, 392:2353-66. 10.1016\/S0140-6736(18)32486-3","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.10.016","article-title":"Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castration-resistant prostate cancer: the CABADOC trial","volume":"81","author":"Baciarello G","year":"2022","unstructured":"Baciarello G, Delva R, Gravis G, et al.. Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castration-resistant prostate cancer: the CABADOC trial. Eur Urol. 2022, 81:234-40. 10.1016\/j.eururo.2021.10.016","journal-title":"Eur Urol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/iju.70019","article-title":"Current evidence on cabazitaxel for prostate cancer therapy: a narrative review","volume":"32","author":"Suzuki K","year":"2025","unstructured":"Suzuki K, Matsuyama H, Matsubara N, Kazama H, Ueno F, Uemura H. Current evidence on cabazitaxel for prostate cancer therapy: a narrative review. Int J Urol. 2025, 32:475-87. 10.1111\/iju.70019","journal-title":"Int J Urol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13957","article-title":"Prognostic impact of prior androgen receptor axis-targeting agents in cabazitaxel chemotherapy after docetaxel","volume":"40","author":"Shiota M","year":"2020","unstructured":"Shiota M, Nakamura M, Yokomizo A, et al.. Prognostic impact of prior androgen receptor axis-targeting agents in cabazitaxel chemotherapy after docetaxel. Anticancer Res. 2020, 40:335-9. 10.21873\/anticanres.13957","journal-title":"Anticancer Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djac081","article-title":"Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer","volume":"114","author":"Lai LY","year":"2022","unstructured":"Lai LY, Oerline MK, Caram ME, Tsao PA, Kaufman SR, Hollenbeck BK, Shahinian VB. Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer. J Natl Cancer Inst. 2022, 114:1127-34. 10.1093\/jnci\/djac081","journal-title":"J Natl Cancer Inst"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01260-x","article-title":"Economic outcomes in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate plus prednisone","volume":"37","author":"Ramaswamy K","year":"2020","unstructured":"Ramaswamy K, Lechpammer S, Mardekian J, et al.. Economic outcomes in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate plus prednisone. Adv Ther. 2020, 37:2083-97. 10.1007\/s12325-020-01260-x","journal-title":"Adv Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4081\/aiua.2021.4.393","article-title":"Novel hormonal agents for metastatic castration-resistant prostate cancer: comparing outcomes. A single-center retrospective study","volume":"93","author":"Jarimba RS","year":"2021","unstructured":"Jarimba RS, Eliseu MN, Pedroso Lima J, et al.. Novel hormonal agents for metastatic castration-resistant prostate cancer: comparing outcomes. A single-center retrospective study. Arch Ital Urol Androl. 2021, 93:393-8. 10.4081\/aiua.2021.4.393","journal-title":"Arch Ital Urol Androl"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-024-02494-7","article-title":"Targeted RT study: results on early toxicity of targeted therapies and radiotherapy","volume":"19","author":"Konnerth D","year":"2024","unstructured":"Konnerth D, Gaasch A, Westphalen CB, et al.. Targeted RT study: results on early toxicity of targeted therapies and radiotherapy. Radiat Oncol. 2024, 19:113. 10.1186\/s13014-024-02494-7","journal-title":"Radiat Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.120","article-title":"Opportunities and challenges of radiotherapy for treating cancer","volume":"12","author":"Schaue D","year":"2015","unstructured":"Schaue D, McBride WH. Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol. 2015, 12:527-40. 10.1038\/nrclinonc.2015.120","journal-title":"Nat Rev Clin Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26041548","article-title":"Circulating epithelial tumor cells (CETC\/CTC) in prostate cancer: potential prognostic marker for the risk of recurrence during radiotherapy","volume":"26","author":"Schott D","year":"2025","unstructured":"Schott D, Pizon M, Drozdz S, M\u00e4urer I, Wurschi G, Pachmann K, M\u00e4urer M. Circulating epithelial tumor cells (CETC\/CTC) in prostate cancer: potential prognostic marker for the risk of recurrence during radiotherapy. Int J Mol Sci. 2025, 26:10.3390\/ijms26041548","journal-title":"Int J Mol Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1967\/s002449910952","article-title":"More advantages in detecting bone and soft tissue metastases from prostate cancer using (18)F-PSMA PET\/CT","volume":"22","author":"Pianou NK","year":"2019","unstructured":"Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. More advantages in detecting bone and soft tissue metastases from prostate cancer using (18)F-PSMA PET\/CT. Hell J Nucl Med. 2019, 22:6-9. 10.1967\/s002449910952","journal-title":"Hell J Nucl Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnab002","article-title":"Hormonal therapy for prostate cancer","volume":"42","author":"Desai K","year":"2021","unstructured":"Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021, 42:354-73. 10.1210\/endrev\/bnab002","journal-title":"Endocr Rev"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0167","article-title":"Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer","volume":"19","author":"Auchus RJ","year":"2014","unstructured":"Auchus RJ, Yu MK, Nguyen S, Mundle SD. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. Oncologist. 2014, 19:1231-40. 10.1634\/theoncologist.2014-0167","journal-title":"Oncologist"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.24456","article-title":"Advances in androgen receptor targeted therapy for prostate cancer","volume":"229","author":"Ahmed A","year":"2014","unstructured":"Ahmed A, Ali S, Sarkar FH. Advances in androgen receptor targeted therapy for prostate cancer. J Cell Physiol. 2014, 229:271-6. 10.1002\/jcp.24456","journal-title":"J Cell Physiol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.4103\/aja.aja_37_18","article-title":"Impact of taxanes on androgen receptor signaling","volume":"21","author":"Bai S","year":"2019","unstructured":"Bai S, Zhang BY, Dong Y. Impact of taxanes on androgen receptor signaling. Asian J Androl. 2019, 21:249-52. 10.4103\/aja.aja_37_18","journal-title":"Asian J Androl"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/389197-comparative-effectiveness-of-management-strategies-for-stage-iv-prostate-cancer-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T09:11:34Z","timestamp":1754385094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/389197-comparative-effectiveness-of-management-strategies-for-stage-iv-prostate-cancer-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.89396","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,8,5]]}}}